Sialyl Lewis Antigens: Association with Muc5ac Protein and Correlation with Post-Operative Recurrence of Non-Small Cell Lung Cancer
Resource
LUNG CANCER v.47 n.1 pp.59-67
Journal
LUNG CANCER
Journal Volume
v.47
Journal Issue
n.1
Pages
59-67
Date Issued
2005
Date
2005
Author(s)
YU, CHONG-JEN
Abstract
Sialyl Lewis antigens (sLex/a) are cancer-associated carbohydrate determinants, serve as ligands of the selectin family and are associated with hematogenous metastasis of cancer. So far, the clinicopathologic values of sialyl Lewis x (sLex) and sialyl Lewis a (sLea) in lung cancer have remained controversial. Using immunohistochemistry, the expressions of sLex and sLea antigens, and an airway mucin ( MUC5AC) protein, which was supposed to be the major carrying protein of sialyl Lewis moieties, were studied in surgically resected tumor tissues of 61 patients with stages I or II NSCLC. Thirty-two (52.5%) of the 61 studied subjects were found to be positive for expression of sLea, 40 (65.6%) were positive for expression of sLex, and 16 (26. 2%) were positive for MUC5AC protein. Both the expression of sLex and MUC5AC were associated with adenocarcinoma subtype. Patients bearing tumors with MUC5AC and/or sLex expression had a higher probability of post-operative distant metastasis. Survival analysis demonstrated that patients bearing tumors with expression of sLex antigen or MUC5AC had shorter overall survival. The multivariate logistic regression showed that age >65 years old (OR = 0. 207, 95% CI= 0.075–0. 569, P = 0.002), nodal status (OR = 6. 575, 95% CI = 2.459–17.583, P < 0. 001), and MUC5AC (OR = 5 . 545, 95% CI = 1.998–15.386, P = 0.001) were independent factors affecting survival. We concluded that the expression of sLex was related to MUC5AC protein, while patients with tumors co- expressing both MUC5AC and sLex antigen had the worst survival.
Subjects
Lung cancer
Carbohydrate antigen
Mucin
Glycosylation
SDGs
Type
journal article